Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv Mecarbil in HFrEF (GALACTIC-HF)
NCT02929329Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Jan 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), sponsored by Cytokinetics. Started Jan 2017; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02929329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929329.